

NCT02902120 Raw comparison:

Summary:
CHIA has 26 criteria while your personal folder has 31 criteria
Total found criteria: 26/26
Total not Found: 0/26
Total Extra: 5
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ At least 18 years of age at the time of screening  │ At least 18 years of age at the time of screening  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Have stable renal function for one month (30 days) │ Have stable renal function for one month (30 days) │
│ prior to enrollment                                │ prior to enrollment                                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Have Chronic HCV infection prior to                │ Have Chronic HCV infection prior to                │
│ transplantation with documented HCV viremia = 1    │ transplantation with documented HCV viremia ≥ 1    │
│ 000 IU/ml at screening and either documented HCV   │ 000 IU/ml at screening and either documented HCV   │
│ Ab positivity or HCV viremia = 1 000 IU/ml at      │ Ab positivity or HCV viremia ≥ 1 000 IU/ml at      │
│ least 6 months prior to enrollment                 │ least 6 months prior to enrollment                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Documented genotype 1 HCV infection prior to       │ Documented genotype 1 HCV infection prior to       │
│ enrollment and after their transplant in the post- │ enrollment and after their transplant in the post- │
│ transplantation cohort                             │ transplantation cohort                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ HCV disease staging within 12 months prior to      │ HCV disease staging within 12 months prior to      │
│ enrollment by liver biopsy transient elastography  │ enrollment by liver biopsy transient elastography  │
│ or biochemical testing                             │ or biochemical testing                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Be able to give informed consent and comply with   │ Be able to give informed consent and comply with   │
│ study guidelines                                   │ study guidelines                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of childbearing age will be required to have │ Women of childbearing age will be required to have │
│ a negative pregnancy test at enrollment and use    │ a negative pregnancy test at enrollment and use    │
│ birth control throughout the duration of treatment │ birth control throughout the duration of treatment │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ On the transplant waiting list followed by the     │ On the transplant waiting list followed by the     │
│ University of Maryland's nephrology clinic or the  │ University of Maryland's nephrology clinic or the  │
│ Baltimore VA's nephrology clinic                   │ Baltimore VA's nephrology clinic                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ On chronic hemodialysis not yet on the transplant  │ On chronic hemodialysis not yet on the transplant  │
│ list and followed in the University's hemodialysis │ list and followed in the University's hemodialysis │
│ center or in the University's nephrology clinic    │ center or in the University's nephrology clinic    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Have chronic kidney disease with GFR <50           │ Have chronic kidney disease with GFR \<50          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Documented positive hepatitis B (HBV) surface      │ Documented positive hepatitis B (HBV) surface      │
│ antigen and/or HBV DNA prior to enrollment         │ antigen and/or HBV DNA prior to enrollment         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any prior exposure to HCV protease inhibitor       │ Any prior exposure to HCV protease inhibitor       │
│ therapy                                            │ therapy                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ HIV co-infection if on a protease inhibitor based  │ HIV co-infection if on a protease inhibitor based  │
│ regimen                                            │ regimen                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Increase in creatinine of 15% or greater within    │ Increase in creatinine of 15% or greater within    │
│ one month (30 days) of the screening visit         │ one month (30 days) of the screening visit         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of hepatocellular carcinoma at the time   │ Evidence of hepatocellular carcinoma at the time   │
│ of enrollment                                      │ of enrollment                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Liver disease caused by an etiology other than HCV │ Liver disease caused by an etiology other than HCV │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ F4 or decompensated cirrhotic patients             │ F4 or decompensated cirrhotic patients             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Child Pugh class B or C                            │ Child Pugh class B or C                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ AST or ALT >350 within 6 months prior to           │ AST or ALT \>350 within 6 months prior to          │
│ enrollment                                         │ enrollment                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Albumin < 3g/dL at the time of enrollment          │ Albumin \< 3g/dL at the time of enrollment         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Platelet count < 75 at the time of enrollment      │ Platelet count \< 75 at the time of enrollment     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of clinically significant allergy or       │ History of clinically significant allergy or       │
│ adverse event with protease inhibitors             │ adverse event with protease inhibitors             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Evidence of the acquisition of HCV at the time of  │ Evidence of the acquisition of HCV at the time of  │
│ or after transplantation                           │ or after transplantation                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant or breastfeeding women                    │ Pregnant or breastfeeding women                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Cyclosporine St John's Wort Efavirenz Phenytoin    │ Cyclosporine St John's Wort Efavirenz Phenytoin    │
│ Carbamazepine Bosentan HIV protease inhibitors     │ Carbamazepine Bosentan HIV protease inhibitors     │
│ modafinil ketoconazole or rifampin use within 7    │ modafinil ketoconazole or rifampin use within 7    │
│ days of enrollment                                 │ days of enrollment                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Coadministration of more than 20 mg atorvastatin   │ Coadministration of more than 20 mg atorvastatin   │
│ 10 mg rosuvastatin 20 mg of fluvastatin lovastatin │ 10 mg rosuvastatin 20 mg of fluvastatin lovastatin │
│ or simvastatin                                     │ or simvastatin                                     │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒══════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                              │
╞══════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Inclusion Criteria Specific to the Post-transplant Arm                                               │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ • Patients will have undergone renal transplantation no greater than five years prior to enrollment  │
│ and will be followed in our University's nephrology and infectious disease clinic They will all have │
│ stable renal function at the time of enrollment                                                      │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Inclusion Criteria Specific to the Pre-transplant Arm                                                │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Patients will either be                                                                              │
├──────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                    │
╘══════════════════════════════════════════════════════════════════════════════════════════════════════╛